Polar Asset Management Partners Inc. Has $285,000 Holdings in Denali Therapeutics Inc. $DNLI

Polar Asset Management Partners Inc. lessened its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 96.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,952 shares of the company’s stock after selling 530,140 shares during the period. Polar Asset Management Partners Inc.’s holdings in Denali Therapeutics were worth $285,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Denali Therapeutics in the 1st quarter valued at $41,000. GF Fund Management CO. LTD. acquired a new position in Denali Therapeutics during the 4th quarter worth $62,000. Point72 Hong Kong Ltd acquired a new position in Denali Therapeutics during the 4th quarter worth $65,000. Finally, GAMMA Investing LLC lifted its position in Denali Therapeutics by 253.8% during the 1st quarter. GAMMA Investing LLC now owns 7,953 shares of the company’s stock worth $108,000 after acquiring an additional 5,705 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Transactions at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 495,282 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the transaction, the chief executive officer owned 253,071 shares of the company’s stock, valued at $3,796,065. This represents a 66.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Alexander O. Schuth sold 2,937 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider directly owned 242,346 shares of the company’s stock, valued at $3,291,058.68. This trade represents a 1.20% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 501,962 shares of company stock worth $7,520,799. 12.50% of the stock is currently owned by company insiders.

Denali Therapeutics Stock Performance

NASDAQ:DNLI opened at $15.43 on Friday. The firm’s 50-day moving average is $14.55 and its 200-day moving average is $14.60. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -5.51 and a beta of 1.23.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same quarter in the prior year, the company posted ($0.59) EPS. Equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

DNLI has been the subject of a number of research analyst reports. Bank of America cut their target price on shares of Denali Therapeutics from $28.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, May 19th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Finally, Morgan Stanley cut their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, August 18th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $33.62.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.